Balanced news tone
News Sentiment
QURE sentiment intelligence
Uniqure NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
49
Balanced news tone
37 relevant articles
Price is moving more forcefully than the current news tone suggests.
85/100 classification confidence.
directly relevant articles
high-authority source matches
+67.9% over one week, +91.4% over four weeks, trend active, and materially above fair value.
uniQure (QURE) CEO sells 206,100 shares and exercises stock options
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
85/100 classification
One-week reaction
67.9%
Price confirming higher
Trend fit
Trend active
91.4% over four weeks
Fair value
226.5%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
29
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
uniQure (QURE) CEO sells 206,100 shares and exercises stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:31
- Source
- Stock Titan
Stock Titan
Direct company coverage
uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:05
- Source
- Stock Titan
Stock Titan
Direct company coverage
uniQure (QURE) director Jack Kaye sells shares after exercising stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 11:54
- Source
- Stock Titan
GuruFocus
Direct company coverage
uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 11:29
- Source
- GuruFocus
Stock Titan
Direct company coverage
uniQure (QURE) shows mixed but promising early AMT-260 MTLE results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Jun 2026 10:50
- Source
- Stock Titan
simplywall.st
Direct company coverage
uniQure (QURE) Stock Could Be 12% Undervalued After FDA Backs AMT 130 Filing Path
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 13:28
- Source
- simplywall.st
Market source
Direct company coverage
uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 19 Jun 2026 10:11
- Source
- Market source
Market source
Direct company coverage
uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 06:15
- Source
- Market source
Stock Titan
Direct company coverage
uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 21:57
- Source
- Stock Titan
Market source
Direct company coverage
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jun 2026 11:30
- Source
- Market source
Investor's Business Daily
Direct company coverage
UniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 20:13
- Source
- Investor's Business Daily
CNBC
Direct company coverage
Stocks making the biggest moves midday: SpaceX, JPMorgan, UniQure, Intel, Figma, Nano Nuclear & more
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 16:37
- Source
- CNBC
Stock Titan
Direct company coverage
uniQure (QURE) investors approve share plan, charter and board at 2026 AGM
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 20:30
- Source
- Stock Titan
Stock Titan
Direct company coverage
[144] uniQure N.V. SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 20:00
- Source
- Stock Titan
AD HOC NEWS
Direct company coverage
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 26 May 2026 07:00
- Source
- AD HOC NEWS
Market source
Direct company coverage
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- Stock Titan
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
PR Newswire
Direct company coverage
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 27 Mar 2026 07:00
- Source
- PR Newswire
Kavout
Direct company coverage
What Just Happened with uniQure's Earnings and FDA Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Mar 2026 16:07
- Source
- Kavout
Stock Titan
Direct company coverage
uniQure NV (QURE) Form 144: 16,499 RSUs vest; insider sold 6,217 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- Stock Titan
Market source
Direct company coverage
uniQure N.V. Q4 2025 Earnings Call Summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Mar 2026 08:00
- Source
- Market source